VLS 211
Alternative Names: VLS-211Latest Information Update: 16 Jun 2021
At a glance
- Originator VelosBio
- Class Anthracyclines; Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates; Immunotherapies
- Mechanism of Action DNA intercalators; Immunostimulants; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Ewing's sarcoma; Precursor B-cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 10 Apr 2021 Preclinical trials in Ewing's Sarcoma in USA (Parenteral), prior to April 2021
- 10 Apr 2021 Preclinical trials in Precursor B-cell lymphoblastic leukaemia-lymphoma in USA (Parenteral), prior to April 2021
- 10 Apr 2021 Pharmacodynamics data from a preclinical trials in Ewing's Sarcoma and Precursor B-cell lymphoblastic leukaemia-lymphoma presented at the 112th Annual Meeting of the American Association for Cancer Research